Rezolute/$RZLT
1D1W1MYTD1Y5YMAX
Capital at risk
About Rezolute
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
- Ticker
- $RZLT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 68
- Headquarters
- Redwood City, United States
- Website
- www.rezolutebio.com
Rezolute Metrics
BasicAdvanced
$408M
-
-$0.80
0.67
-
Price and volume
Market cap
$408M
Beta
0.67
52-week high
$11.46
52-week low
$1.07
Average daily volume
1.4M
Financial strength
Current ratio
15.842
Quick ratio
15.611
Long term debt to equity
0.004
Total debt to equity
0.01
Profitability
EBITDA (TTM)
-85.823
Management effectiveness
Return on assets (TTM)
-48.74%
Return on equity (TTM)
-81.73%
Valuation
Price to book
3.5
Price to tangible book (TTM)
3.5
Price to free cash flow (TTM)
-5.393
Free cash flow yield (TTM)
-18.54%
Free cash flow per share (TTM)
-0.725
Growth
Earnings per share change (TTM)
-27.82%
3-year earnings per share growth (CAGR)
-10.90%
10-year earnings per share growth (CAGR)
-30.15%
What the Analysts think about Rezolute
Analyst ratings (Buy, Hold, Sell) for Rezolute stock.
Analyst projections of the future price of Rezolute stock.
Bulls say / Bears say
The FDA is still reviewing Rezolute’s additional sunRIZE data after acknowledging limitations in self-monitored glucose measures. That keeps a potential regulatory route open despite the trial setback. (Rezolute)
Rezolute’s tumour hyperinsulinism programme provides a second potential route to value: a case series reported that 75% of patients receiving intravenous dextrose or total parenteral nutrition through the expanded-access programme stopped those therapies completely. (Rezolute)
The pivotal sunRIZE study failed to meet its primary endpoint and key secondary endpoint, with the treatment effect not reaching statistical significance against placebo. This weakens the evidence for approval in congenital hyperinsulinism. (Rezolute)
The FDA review is taking place outside the customary formal meeting process and has no specific timetable for feedback or agreement on next steps. Rezolute therefore lacks a clear filing route or regulatory catalyst. (Rezolute)
Rezolute remains pre-revenue and loss-making: cash, cash equivalents and investments fell to $120.3 million by 31 March 2026 from $167.9 million nine months earlier, while the quarter produced a $16.2 million net loss. Continued development could require further fundraising and shareholder dilution. (Rezolute)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.
Rezolute Financial Performance
Revenues and expenses
Rezolute Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Rezolute
Fund name | Fund size | $RZLT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.